Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Digital Realty Trust, Inc. (DLR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Digital Realty Trust, Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Digital Realty Trust, Inc. trades at $179 (market cap $66.75B). The key difference: Digital Realty Trust, Inc. is the larger of the two by market cap, and Digital Realty Trust, Inc. pays a 2.7% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | DLR | |
|---|---|---|
Market Cap | $39.89B | $66.75B |
Sector | Health | Real Estate |
52-Week High | $491.22 | $203.91 |
52-Week Low | $278.09 | $147.93 |
Enterprise Value | $38.15B | $84.27B |
Dividend Yield | — | 2.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Digital Realty Trust (DLR) trades at $180.41, up 0.6% on the day, with a bearish technical signal despite strong analyst consensus. The stock shows robust fundamentals with revenue growth to $6.11B in 2025 and net income margin of 21.73%, though valuation ratios like P/E of 47.85 appear elevated. Recent news highlights a $7.8B acquisition of Blackstone's data center stake, expanding its hyperscale portfolio amid AI-driven demand.
Outlook remains positive with a consensus price target of $218.77, implying 21% upside, supported by AI infrastructure expansion. Key risks include high debt levels, execution challenges from recent deals, and interest rate sensitivity. Institutional sentiment is bullish with 60% buy ratings, but technical weakness near support at $178 warrants caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Digital Realty Trust, Inc.
Digital Realty owns and operates nearly 300 data centers worldwide. It has more than 35 million rentable square feet across five continents. Digital's offerings range from retail co-location, where an enterprise may rent a single cabinet and rely on Digital to provide all the accommodations, to cold shells, where hyperscale cloud service providers can simply rent much, or all, of a barren, power-connected building. In recent years, Digital Realty has de-emphasized cold shells and now primarily provides higher-level service to tenants, which outsource their related IT needs to Digital. Digital Realty has also moved more into the co-location business, increasingly serving enterprises and facilitating network connections. Digital Realty operates as a real estate investment trust.
Read more on DLR →
